CoChat
Sign Up
Cited by 233Neurotransmitter Receptor Influence on BehaviorParkinson's Disease Mechanisms and TreatmentsSubstance Abuse Treatment and Outcomes

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers

Johanson, Chris-Ellyn, Frey, Kirk A., Lundahl, Leslie H., Keenan, Pamela, Lockhart, Nancy, Roll, John, Galloway, Gantt P., Koeppe, Robert A., Kilbourn, Michael R., Robbins, Trevor, Schuster, Charles R.·2006·Psychopharmacology
DOI 10.1007/s00213-006-0330-6
Open this paper in CoChat — free account

Abstract

Objective Preclinical investigations have established that methamphetamine (MA) produces long-term changes in dopamine (DA) neurons in the striatum. Human studies have suggested similar effects and correlated motor and cognitive deficits. The present study was designed to further our understanding of changes in brain function in humans that might result from chronic high dose use of MA after at least 3 months of abstinence.Method Brain function in abstinent users was compared to controls using neuroimaging of monoamine transporters and cognitive assessment. Striatal levels of DA transporter (DAT) and vesicular monoamine transporter type-2 (VMAT2) were determined using [11C]methylphenidate and [11C]dihydrotetrabenazine positron emission tomography, respectively. Cognitive function was evaluated using tests of motor function, memory, learning, attention, and executive function.Results Striatal DAT was approximately 15% lower and VMAT2 was 10% lower in MA abusers across striatal subregions. The MA abusers performed within the normal range but performed more poorly compared to controls on three of the 12 tasks.Conclusions Failure to find more substantial changes in transporter levels and neurocognitive function may be attributed to the length of time that MA users were abstinent (ranging from 3 months to more than 10 years, mean 3 years), although there were no correlations with length of abstinence. Persistent VMAT2 reductions support the animal literature indicating a toxic effect of MA on nigrostriatal nerve terminals. However, the magnitude of the MA effects on nigrostriatal projection integrity is sufficiently small that it is questionable whether clinical signs of DA deficiency are likely to develop.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00213-006-0330-6

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Cited by

Sorted by citations

See all 233

Related

Metadata

Authors
Johanson, C.-E., Frey, K. A., Lundahl, L. H., Keenan, P., Lockhart, N., Roll, J., Galloway, G. P., Koeppe, R. A., Kilbourn, M. R., Robbins, T., & Schuster, C. R.
Affiliations
  • Wayne State University (US)
  • University of Michigan (US)
  • Friends Research Institute (US)
  • University of Cambridge (GB)
Corresponding author
Johanson, Chris-Ellyn
ORCID
Venue
Psychopharmacology
Publisher
Springer Science and Business Media LLC
Published
2006-03-03
Volume
185
Issue
3
Pages
327-338
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
DOI
10.1007/s00213-006-0330-6
OpenAlex
W1973774749
Cited by
233
References
49
Citations by year
2026: 2 · 2025: 3 · 2024: 6 · 2023: 5 · 2022: 7 · 2021: 11 · 2020: 30 · 2019: 8 · 2018: 9 · 2017: 12 · 2016: 11 · 2015: 15 · 2014: 12 · 2013: 19 · 2012: 21
FWCI
4.40
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Deep Blue (University of Michigan) (submittedVersion)
Funders
  • National Institutes of Health (5r01da012458-03, 5r21da014392-02)
  • National Institute on Drug Abuse (DA14392, DA12458, R01DA010641, R01 DA10641)
  • National Institute of Neurological Disorders and Stroke (NS-15655)
  • National Center for Research Resources (RR00042, M01RR000042)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
methamphetamine, abstinence, cognitive function, nigrostriatal pathway, dopamine transporter, vesicular monoamine transporter 2, striatum, dopamine deficiency, monoamine transporters, executive function, learning and memory, attention, motor function
MeSH terms
Adolescent, Adult, Cognition, Corpus Striatum, Dopamine, Female, Humans, Male, Methamphetamine, Middle Aged, Psychological Tests, Substantia Nigra, Amphetamine-Related Disorders, Dopamine Plasma Membrane Transport Proteins, Vesicular Monoamine Transport Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review